PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected to Post FY2026 Earnings of ($1.41) Per Share

PTC Therapeutics, Inc. (NASDAQ:PTCT) – William Blair issued their FY2026 earnings estimates for PTC Therapeutics in a research note issued to investors on Friday, August 9th. William Blair analyst S. Corwin anticipates that the biopharmaceutical company will post earnings of ($1.41) per share for the year. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.87) per share. William Blair also issued estimates for PTC Therapeutics’ FY2027 earnings at $1.63 EPS.

PTCT has been the topic of a number of other research reports. Raymond James upgraded PTC Therapeutics from an “underperform” rating to a “market perform” rating in a report on Monday, May 20th. Jefferies Financial Group lifted their price objective on PTC Therapeutics from $35.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, May 20th. The Goldman Sachs Group upped their target price on shares of PTC Therapeutics from $18.00 to $32.00 and gave the company a “sell” rating in a report on Tuesday, May 28th. Bank of America lifted their price target on shares of PTC Therapeutics from $25.00 to $32.00 and gave the stock an “underperform” rating in a report on Friday, June 21st. Finally, Citigroup upped their price objective on shares of PTC Therapeutics from $18.00 to $26.00 and gave the company a “sell” rating in a research note on Tuesday, May 21st. Three analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, PTC Therapeutics currently has a consensus rating of “Hold” and an average price target of $35.85.

PTC Therapeutics Price Performance

Shares of PTCT opened at $31.87 on Monday. PTC Therapeutics has a 1-year low of $17.53 and a 1-year high of $41.97. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of -4.15 and a beta of 0.65. The firm has a 50 day simple moving average of $33.76 and a 200-day simple moving average of $31.04.

Insider Activity

In related news, CFO Pierre Gravier sold 2,269 shares of PTC Therapeutics stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $34.02, for a total value of $77,191.38. Following the transaction, the chief financial officer now owns 53,531 shares in the company, valued at $1,821,124.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Jerome B. Zeldis sold 20,000 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $38.24, for a total value of $764,800.00. Following the transaction, the director now owns 14,500 shares of the company’s stock, valued at approximately $554,480. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Pierre Gravier sold 2,269 shares of the company’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $34.02, for a total transaction of $77,191.38. Following the sale, the chief financial officer now directly owns 53,531 shares of the company’s stock, valued at $1,821,124.62. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its stake in shares of PTC Therapeutics by 57.9% in the first quarter. Russell Investments Group Ltd. now owns 301,790 shares of the biopharmaceutical company’s stock valued at $8,779,000 after buying an additional 110,670 shares in the last quarter. Vise Technologies Inc. boosted its holdings in PTC Therapeutics by 20.1% in the 4th quarter. Vise Technologies Inc. now owns 12,808 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 2,140 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in PTC Therapeutics by 8.7% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 439,365 shares of the biopharmaceutical company’s stock valued at $12,782,000 after acquiring an additional 35,173 shares in the last quarter. Edgestream Partners L.P. raised its stake in shares of PTC Therapeutics by 49.3% during the first quarter. Edgestream Partners L.P. now owns 53,522 shares of the biopharmaceutical company’s stock valued at $1,557,000 after purchasing an additional 17,681 shares during the period. Finally, Burney Co. acquired a new position in shares of PTC Therapeutics during the first quarter worth $1,223,000.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.